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Introduction
Previous animal studies have reported that the acute
administration of EPO at the onset of myocardial reper-
fusion reduces infarct size by 40-50%. Whether EPO has
the same effect in ST-elevation myocardial infarction
(STEMI) patients undergoing primary percutaneous coro-
nary intervention (PPCI) is unknown.
Purpose
To assess the efficacy of erythropoietin (EPO) as adjunc-
tive therapy to PPCI in STEMI patients using cardiac mag-
netic resonance (CMR) endpoints.
Methods
Fifty one STEMI patients presenting for PPCI within 12
hours of chest pain were randomized to receive either a
single intravenous bolus of EPO (50,000 iu in 10 mls nor-
mal saline) with a further bolus given 24 hours later, or
placebo. Patients with TIMI flow>1, cardiac arrest, cardio-
genic shock or significant coronary collateralization were
excluded. Both patient and cardiologist were blinded to
the treatment allocation. Troponin-T and CK-MB were
measured over 24 hours. CMR scans (LV volumes, LV ejec-
tion fraction-EF, late gadolinium enhancement-LGE,
microvascular obstruction-MVO, infarct-endocardial sur-
face area-ESA) were performed at day 3 and repeated at 4
months.
Results
The groups were matched with no differences in chest
pain to balloon time or area at risk (AAR) by coronary
angiography (modified BARI and APPROACH jeopardy
scores) or CMR (infarct-ESA). There were no significant
differences with respect to LVEF, myocardial infarct size,
or the myocardial salvage index (see table 1). However,
EPO treatment doubled the incidence of MVO and acutely
increased LV size (indexed LV end diastolic and systolic
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(see figure 1 and table 1). On the follow-up CMR scan at
4 months there were no significant differences in myocar-
dial infarct size, LVEF and LV internal dimensions
between the two treatment groups. The figure depicts rep-
resentative early and late gadolinium enhancement short-
axis images showing the presence of significant microvas-
cular obstruction (see *) within an area of infarction (see
arrow) in a patient presenting with an acute LAD myocar-
dial infarct
Conclusion
In this randomized clinical trial, no beneficial effects of
EPO as an adjunct to PPCI were demonstrated-in fact, the
effects were potentially detrimental with an increased
incidence of MVO and greater LV internal dimensions
acutely. This study highlights the importance of CMR end-
points in assessing the efficacy of reperfusion treatment
strategies in acute myocardial infarction.
Table 1: CMR endpoints day 3 post-PPCI
Endpoint Placebo Erythropoietin P value
LVEF 53 ± 11% 51 ± 7% P = 0.26
24 hr AUC Trop-T 101.7 ± 67.5 μg/l 114.6 ± 78.3 μg/l P = 0.56
24 hr AUC CK-MB 3512 ± 2692 μg/l 4682 ± 2946 μg/l P = 0.15
LGE/AAR 67.8 ± 2.0% 71.5 ± 17.0% P = 0.58
Myocardial salvage index 0.36 ± 0.23 0.29 ± 0.17 P = 0.28
MVO (incidence) 42% 82% P = 0.008*
LVEDVi 73 ± 13 ml/m2 84 ± 10 ml/m2 P = 0.003*
LVESVi 34 ± 11 ml/m2 41 ± 9 ml/m2 P = 0.035*Page 2 of 2
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